nach oben

Erschienen in:

01.03.2006 | Original Article

Immunohistochemical expression of p63, p53 and MIB-1 in urinary bladder carcinoma. A tissue microarray study of 158 cases

verfasst von: Eva Compérat, Philippe Camparo, Rachel Haus, Emmanuel Chartier-Kastler, Stephane Bart, Annick Delcourt, Alain Houlgatte, Richard François, Fréderique Capron, Annick Vieillefond

Erschienen in: Virchows Archiv | Ausgabe 3/2006

Einloggen, um Zugang zu erhalten

Abstract

P63 is a member of the p53 family, which plays a role in the differentiation of urothelium and is supposed to play a role in urothelial carcinogenesis. P53 and MIB-1 are recognised in many studies as predictive markers of progression, but few studies in the literature have examined p63. The aims of our study were to explore the expression of p63 in bladder carcinomas and to compare this expression to p53 and MIB-1, as well as to stage and grade. Tissue microarrays were performed on 158 urothelial carcinomas (56 pTa, 45 pT1 and 57≥pT2). Immunohistochemical studies were performed with p63, p53 and MIB-1 antibodies. In our study we observed that p63 immunostaining is present in all cell layers in papillary urothelial neoplasm of low malignant potential (PUNLMP), but partially lost in non-invasive papillary urothelial carcinoma low grade (NILGC) and in pT1/≥pT2 bladder cancers. P53 and MIB-1 displayed lower expression in PUNLMP/NILGC vs non-invasive papillary urothelial carcinoma high grade (NIHGC)/pT1, but there was no correlation between the expression of p63, p53 and MIB-1. Our study demonstrates that p63 expression distinguishes between PUNLMP/NILGC and NIHGC/pT1 (p=4.10⁵). A statistical difference disserving pTa and pT1/≥pT2 with a statistical significance (p<10⁻⁶) could also be observed. P63 should be considered as an additional biomarker that might help pathologists to classify their patients.

Barbieri CE, Barton CE, Pietenpol JA (2003) Delta Np63 alpha expression is regulated by the phosphoinositide 3-kinase pathway. J Biol Chem 278:51408–51414CrossRefPubMed

Cho NH, Kim YB, Park TK, Kim GE, Park K, Song KJ (2003) P63 and EGFR as prognostic predictors in stage IIB radiation-treated cervical squamous cell carcinoma. Gynecol Oncol 91:346–353CrossRefPubMed

DiComo CJ, Urist MJ, Babayan I, Drobnjak M, Hedvat CV, Teruya-Feldstein J, Pohar K, Hoos A, Cordon-Cardo C (2002) p63 expression profiles in human normal and tumor tissue. Clin Cancer Res 8:494–501PubMed

Geddert H, Kiel S, Heep HJ, Gabbert HE, Sarbia M (2003) The role of p63 and deltaNp63 (p40) protein expression and gene amplification in esophageal carcinogenesis. Hum Pathol 34:850–856CrossRefPubMed

Habuchi T, Kinoshita H, Yamada H, Knowles M (1995) Oncogene amplification in urothéliale cancers with p53 gene mutation or MDM2 amplification. J Natl Cancer Inst 86:1331–1335CrossRef

Hagiwara K, McMenamin MG, Miura K, Harris CC (1999) Mutational analysis of the p63/p73L/p51/p40/CUSP/KET gene in human cancer cell lines using intronic primer. Cancer Res 59:14165–14169

Hara T, Kijima H, Yamamoto S, Kenmochi T, Kise Y, Tanaka H, Chino O, Shimada H, Takazawa K, Tanaka M, Inokuchi S, Makuuchi H (2004) Ubiquitous p63 expression in human esophageal squamous cell carcinoma. Int J Mol Med 14:169–173PubMed

Harmes DC, Bresnick E, Lubin EA, Watson JK, Heim KE, Curtin JC, Suskind AM, Lamb J, DiRenzo J (2003) Positive and negative regulation of deltaN-p63 promoter activity by p53 and deltaN-p63-alpha contributes to differential regulation of p53 target genes. Oncogene 22:7607–7616CrossRefPubMed

Harms K, Nozell S, Chen X (2004) The common and distinct target genes of the p53 family transcription factors. Cell Mol Life Sci 61:822–842CrossRefPubMed

10.

Helpap B, Köllermann J (1999) Proliferative pattern of exophytic and superficially invasive and non-invasive low grade urothelial carcinomas. Hum Pathol 30:145–150CrossRefPubMed

11.

Helpap B, Köllermann J (2000) Assessment of basal cell status and proliferative patterns in flat and papillary urothelial lesions: a contribution to the new WHO classification of urothelial tumors of the urinary bladder. Hum Pathol 31:745–750CrossRefPubMed

12.

Helpap B, Schmitz-Dräger B, Hamilton PW, Muzzonigro G, Galosi AB, Kurth KH, Lubaroff D, Waters D, Droller MJ (2003) Molecular pathology of non-invasive urothéliale carcinomas (part I). Virchows Arch 442:309–316PubMed

13.

Holmang S, Johansson SL (2002) Stage Ta-T1 bladder cancer: the relationship between findings at first follow-up cystoscopy and subsequent recurrence and progression. J Urol 167:1634–1637CrossRefPubMed

14.

Jourdan F, Sebbagh N, Compérat E, Mourra N, Flahault A, Olschwang S, Hamelin R, Fléjou JF (2003) Tissue microarray technology: validation in colorectal carcinoma and analysis of p53, hMLH1 and hMSH2 immunohistochemical expression. Virchows Arch 443:115–121CrossRefPubMed

15.

Kaufmann O, Fietze E, Mengs J, Dietel M (2001) Value of p63 and cytokeratin 5/6 as immunohistochemical markers for the differential diagnosis of poorly differentiated and undifferentiated carcinomas. Am J Clin Pathol 116:823–830CrossRefPubMed

16.

Knowles M (2001) What we could do now: molecular pathology of bladder cancer. J Clin Pathol 54:215–221CrossRef

17.

Koga F, Kawakami S, Fujii Y, Saito K, Ohtsuka Y, Iwai et al (2003) Impaired p63 expression associates with poor prognosis and uroplakin III expression in invasive urothéliale carcinoma of the bladder. Clin Cancer Res 9:5501–5507PubMed

18.

Koga F, Kawakami S, Kumagai J, Takizawa T, Ando N, Arai G, Kageyama Y, Kihara K (2003) Impaired Delta Np63 expression associates with reduced beta-catenin and aggressive phenotypes of urothelial neoplasms. Br J Cancer 88:740–747CrossRefPubMed

19.

Langner C, Ratschek M, Tsybrovskyy O, Schips L, Zigeuner R (2003) P63 immunoreactivity distinguishes upper urinary tract transitional-cell carcinoma and renal-cell carcinoma even in poorly differentiated tumors. J Histochem Cytochem 51:1097–1099PubMed

20.

Lebret T, Bohin D, Kassardjan Z, Herve JM, Molinie V, Barre P, Lugagne PM, Botto H (2000) Recurrence, progression and success in stage Ta grade 3 bladder tumors treated with low dose bacillus Calmette–Guerin instillations. J Urol 163:63–67CrossRefPubMed

21.

Little NA, Jochemsen AG (2002) p63. Int J Biochem Cell Biol 34:6–9CrossRefPubMed

22.

Lu ML, Wikman F, Orntoft T, Charytonowicz E, Rabbani F, Zhang Z, Dalbagni G, Pohar KS, Yu G, Cordon-Cardo C (2002) Impact of alterations affecting the p53 pathway in bladder cancer on clinical outcome assessed by conventional and array-based methods. Clin Cancer Res 8:171–179PubMed

23.

Massion PP, Taflan PM, Jamshedur Rahman SM, Yildiz P, Shyr Y, Edgerton ME, Westfall MD, Roberts JR, Pietenpol JA, Carbone DP, Gonzalez AL (2003) Significance of p63 amplification and overexpression in lung cancer development and prognosis. Cancer Res 63(21):7113–7121PubMed

24.

Melino G, Lu X, Gasco M, Crook T, Knight RA (2003) Functional regulation of p73 and p63: development and cancer. Trends Biochem Sci 28:663–670CrossRefPubMed

25.

Moll U (2003) The role of p63 and p73 in tumor formation and progression: coming of age towards clinical usefulness. Clin Cancer Res 9:5437–5441PubMed

26.

Nakanishi K, Kawai T, Torikata C (1996) Immunohistochemical evaluation of p53 oncoprotein in transitional cell carcinoma of the upper urinary tract. Hum Pathol 27:1336–1340CrossRefPubMed

27.

Nocito A, Bubendorf L, Tinner EM, Süss K, Wagner U, Forster T, et al (2001) Microarrays of bladder cancer tissue are highly representative of proliferation index and histological grade. J Pathol 194:349–357CrossRefPubMed

28.

Park BJ, Lee SJ, Lee KSJ, Lee CH, Chang SG, Park JH et al (2000) Frequent alteration of p63 expression in human primary bladder carcinomas. Cancer Res 60:3370–3374PubMed

29.

Pelosi G, Pasini F, Olsen Stenholm C, Pastorino U, Maisonneuve P, Sonzogni A, Maffini F, Pruneri G, Fraggetta F, Cavallon A, Roz E, Iannucci A, Bresaola E, Viale G (2002) p63 immunoreactivity in lung cancer: yet another player in the development of squamous cell carcinomas? J Pathol 198:100–109CrossRefPubMed

30.

Reis-Filho JS, Simpson PT, Martins A, Preto A, Gärtner F, Schmitt FC (2003) Distribution of p63, cytokeratins 5/6 and cytokeratin 14 in 51 normal and 400 neoplastic human tissue samples using TARP-4 multi-tumor tissue microarray. Virchows arch 443:122–132CrossRefPubMed

31.

Ribeiro-Silva A, Zambelli Ramalho LN, Britto Garcia S, Zucoloto S (2003) The relationship between p63 and p53 expression in normal and neoplastic breast tissue. Arch Pathol Lab Med 127:336–340PubMed

32.

Richter J, Jiang F, Gorog JP (1997) Marked genetic differences between stage pTa and stage pT1 papillary bladder cancer detected by comparative genomic hybridization. Cancer Res 57:2860–2864PubMed

33.

Sandberg AA (2002) Cytogenetics and molecular genetics of bladder cancer: a personal view. Am Med Genet 115:173–182CrossRef

34.

San Miguel Fraile P, Anton Badiola I, Ortiz Rey JA, Alvarez Alvarez C, Fernandez Costas A, Lago Fernandez M, Pelaez Boismorand E, Zungri Telo E, De La Fuente Buceta A (2003) Comparative study of the expression of p53, Ki-67, bcl-2 and CK20 in superficial transitional carcinoma of the bladder: correlation with recurrence, histological grade, and clinical stage. Actas Urol Esp 27:587–593PubMed

35.

Santos L, Amaro T, Costa C, Pereira S, Bento MJ, Lopes P et al (2003) Ki-67 index enhances the prognostic accuracy of the urothéliale superficial bladder carcinoma risk group classification. Int J Cancer 105:267–272CrossRefPubMed

36.

Senoo M, Matsumura Y, Habu S (2002) TAp63gamma (p51A) and dNp63alpha (p73L), two major isoforms of the p63 gene, exert opposite effects on the vascular endothelial growth factor (VEGF) gene expression. Oncogene 21:2455–2465CrossRefPubMed

37.

Shariat SF, Kim J, Raptidis G, Ayala G, Lerner S (2003) Association of p53 and p21 expression with clinical outcome in patients with carcinoma in situ of the urinary bladder. Urology 61:1140–1145CrossRefPubMed

38.

Signoretti S, Waltregny D, Dilks J, Isaac B, Lin D, Garraway L, Yang A Montironi R, McKeon F, Loda M (2000) p63 is a prostate basal cell marker and is required for prostate development. Am J Pathol 157:1769–1775PubMed

39.

Smith ND, Rubenstein JN, Eggener SE, Kozlowski JM (2003) The p53 tumor suppressor gene and nuclear protein: basic science review and relevance in the management of bladder cancer. J Urol 169:1219–1228CrossRefPubMed

40.

Soloway MS, Sofer M, Vaidya A (2002) Contemporary management of stage T1 transitional cell carcinoma of the bladder. J Urol 167:1573–1583CrossRefPubMed

41.

Strano S, Fontemaggi G, Costanzo A, Rizzo MG, Monti O, Baccarini A, Del Sal G, Levrero M, Sacchi A, Oren M, Blandino G (2002) Physical interaction with human tumor-derived p53 mutants inhibits p63 activities. J Biol Chem 277:18817–18826CrossRefPubMed

42.

Thurfjell N, Coates PJ, Uusitalo T, Mahani D, Dabelsteen E, Dahlqvist A, Sjostrom B, Roos G, Nylander K (2004) Complex p63 mRNA isoform expression patterns in squamous cell carcinoma of the head and neck. Int J Oncol 25(1):27–35PubMed

43.

Tiguert R, Lessard A, So A, Fradet Y (2002) Prognostic markers in muscle invasive bladder cancer. World J Urol 20:190–195PubMed

44.

Urist M J, Di Como CJ, Lu ML, Charytonowicz E, Verbel D, Crum CP et al (2002) Loss of p63 expression is associated with tumor progression in bladder cancer. Am J Pathol 161:1199–1206PubMed

45.

World Health Organization Classification of Tumors (2004) Tumors of the urinary system and male genital organs. In: Eble J et al (eds) IARC, Lyon

46.

Wu G, Nomoto S, Hoque MO, Dracheva T, Osada M, Lee CC, Dong SM, Guo Z, Benoit N, Cohen Y, Rechthand P, Califano J, Moon CS, Ratovitski E, Jen J, Sidransky D, Trink B (2003) DeltaNp63alpha and TAp63alpha regulate transcription of genes with distinct biological functions in cancer and development. Cancer Res 63:2351–2357PubMed

47.

Yan Y, Andriole GL, Humphrey PA, Kibel AS (2002) Patterns of multiple recurrences of superficial (Ta/T1) transitional cell carcinomas of bladder and effects of clinicopathologic and biochemical factors. Cancer 95:1239–1246CrossRefPubMed

48.

Yang A, Schweitzer R, Sun D, Kaghad M, Walker N, Bronson RT, Tabin C, Sharpe A, Caput D, Crum C, McKeon F (1999) p63 is essential for regenerative proliferation in limb, craniofacial, and in epithelial development. Nature 398:714–718CrossRefPubMed

49.

Zigeuner R, Tsybrovskyy O, Ratschek M, Rehak P, Lipsky K, Langner C (2004) Prognostic impact of p63 and p53 expression in upper urinary tract transitional cell carcinomas. Urology 63:1079–1083CrossRefPubMed

Titel: Immunohistochemical expression of p63, p53 and MIB-1 in urinary bladder carcinoma. A tissue microarray study of 158 cases
verfasst von: Eva Compérat
Philippe Camparo
Rachel Haus
Emmanuel Chartier-Kastler
Stephane Bart
Annick Delcourt
Alain Houlgatte
Richard François
Fréderique Capron
Annick Vieillefond
Publikationsdatum: 01.03.2006
Verlag: Springer-Verlag
Erschienen in: Virchows Archiv / Ausgabe 3/2006
Print ISSN: 0945-6317
Elektronische ISSN: 1432-2307
DOI: https://doi.org/10.1007/s00428-005-0092-2

Springer Medizin

Immunohistochemical expression of p63, p53 and MIB-1 in urinary bladder carcinoma. A tissue microarray study of 158 cases

Abstract

Neu im Fachgebiet Pathologie

Molekularpathologische Untersuchungen im Wandel der Zeit

Vergleichende Pathologie in der onkologischen Forschung

Gastrointestinale Stromatumoren

Personalisierte Medizin in der Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2006

Pulmonary manifestation of a Langerhans cell sarcoma: case report and review of the literature

Small-cell variant of renal oncocytoma with dominating solid growth pattern: a potential diagnostic pitfall

Announcements

Pathologic examination of the axillary sentinel lymph nodes in patients with early-stage breast carcinoma: current and resolving controversies on the basis of the European Institute of Oncology experience

Biphasic solitary fibrous tumour: a report of two cases with epithelioid features

Chronic urticaria is associated with mast cell infiltration in the gastroduodenal mucosa

Neu im Fachgebiet Pathologie

Molekularpathologische Untersuchungen im Wandel der Zeit

Vergleichende Pathologie in der onkologischen Forschung

Gastrointestinale Stromatumoren

Personalisierte Medizin in der Onkologie